A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
Titel:
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
Auteur:
Giles, Francis Verstovsek, Srdan Faderl, Stefan Vey, Norbert Karp, Judy Roboz, Gail Khan, Khuda Dan Cooper, Maureen Bilgrami, Syed Fazl Ali Ferrant, Augustin Daenen, Simon Karsten, Verena Cahill, Ann Albitar, Maher Kantarjian, Hagop O’Brien, Susan Feldman, Eric